According to Copley, interest in the use of Abbreviated Impactor Measurement (AIM) was clear at the EPAG (European Pharmaceutical Aerosol Group)-sponsored workshop on drug delivery to the lungs.
Here, presenters from a number of leading pharmaceutical companies shared experimental data comparing AIM results.
New instrumentation, such as the Fast Screening Impactor (FSI) and Fast Screening Andersen (FSA), from Copley Scientific, were shown to deliver data comparable to conventional cascade impaction in less time.
Aerodynamic particle-size distribution is a routine measurement for all inhaled products using full-resolution cascade impaction.
AIM reduces measurement times by focusing on the fine particle fraction - typically the sub-5um portion of the dose that is considered to deposit deep in the lung - and has the potential to accelerate information gathering, especially for rapid screening in research and development and routine QC.
Pharmaceutical industry presenters shared data comparing AIM results with those obtained using full-resolution impaction.
There was broad consensus that good agreement is achievable with both the FSI and FSA, two of the commercially available systems discussed, for nebulizers and metered dose inhalers.
Data on dry powder inhalers (DPI) suggests that further research is needed in this area.
Every company reported significant savings in analytical time with AIM, some also reporting reduced solvent consumption.
The workshop concluded with a discussion of the results and the way forward, covering: the need to better understand the kinetics of DPI testing; the likely attitude of the regulators and the criticality of this in AIM uptake; and the requirement for further studies to support the validity of the technique, including information on the performance of the Twin Impinger.
The AIM conversation will continue through the year with further events planned at IPAC-RS (29-31 March, Maryland, US), RDD 2011 (3-6 May, Berlin, Germany) and ISAM (18-22 June, Rotterdam, Holland).
